Showing 1801-1810 of 10397 results for "".
The Penalty Era: The Next Phase in Medicine
https://practicaldermatology.com/topics/practice-management/the-penalty-era-the-next-phase-in-medicine/21159/New proposed rule changes spell an uncertain future for the Meaningful Use program.Make the Most of Online Press Releases
https://practicaldermatology.com/topics/practice-management/make-the-most-of-online-press-releases/21158/Online press releases can help boost search engine optimization for your website— when done well.Who's Responsible for Your Receivables?
https://practicaldermatology.com/topics/general-topics/PD0109_02-php/22889/When it comes to timely collection of payments, different staff members have important responsibilities.Monitoring Biologic Therapy In Psoriasis: A Primer
https://practicaldermatology.com/topics/psoriasis/monitoring-biologic-therapy-in-psoriasis-a-primer/20931/Treatments are generally safe and well-tolerated, however, prescribers must monitor for risk factors.Attention, Please! Why Dermatologists Need to Confront Burnout
https://practicaldermatology.com/topics/practice-management/attention-please-why-dermatologists-need-to-confront-burnout/20557/Raising awareness of the problem is essential to finding a solution.Cracking the Codes: Telemedicine Rolls Forward
https://practicaldermatology.com/topics/practice-management/cracking-the-codes-telemedicine-rolls-forward/23226/Here’s a primer on the new online digital E/M service codes.An Update on At-Home UVB Phototherapy
https://practicaldermatology.com/topics/general-topics/an-update-on-at-home-uvb-phototherapy/21786/At-home options increase accessibility to phototherapy, which is effective and generally safe for psoriasis management.Biosimilar Medicines in Dermatology: Key Aspects
https://practicaldermatology.com/topics/psoriasis/biosimilar-medicines-in-dermatology-key-aspects/22929/After the recent enactment of a specific approval pathway for biosimilars and publication of the first draft guidelines on biosimilar product development by the FDA, biosimilars are expected to be available in the US soon.What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis
https://practicaldermatology.com/topics/psoriasis/what-does-efficacy-cost-evidence-for-relative-cost-effectiveness-of-biologic-therapies-for-psoriasis/23128/Despite high costs, evidence suggests that biologics are cost-effective options for moderate to severe psoriasis because of their efficacy.The Importance of Diversity in Clinical Trials
https://practicaldermatology.com/issues/april-2025/the-importance-of-diversity-in-clinical-trials/35606/The disproportionate representation of certain segments of the population in clinical trials is no secret, and research has shown that psoriasis studies are the least racially diverse of all dermatology studies in the US.